308242-41-3

Upstream product

• 308242-14-0 (S)-3-(7-chloro-2-oxo-5-(2-fluorophenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionic acid methyl ester 
• 784-38-3 2-amino-5-chloro-2'-fluorobenzophenone 
• 45214-91-3 (2S)-2-[(tert-butoxy)carbonylamino]-4-(methoxycarbonyl)butanoic acid 

Downstream Products

• 308243-44-9 3-[7-chloro-5-(2-fluoro-phenyl)-2-(2-hydroxy-propylamino)-3H-benzo[e][1,4]diazepin-3-yl]-propionic acid methyl ester 
• 308242-57-1 3-[8-chloro-6-(2-fluoro-phenyl)-2-methyl-4H-3,5,10b-triaza-benzo[e]azulen-4-yl]-propionic acid methyl ester 
• 308242-56-0 3-[8-chloro-6-(2-fluoro-phenyl)-1-methyl-4H-3,5,10b-triaza-benzo[e]azulen-4-yl]-propionic acid methyl ester 
• 308242-55-9 3-[8-chloro-6-(2-fluoro-phenyl)-4H-3,5,10b-triaza-benzo[e]azulen-4-yl]-propionic acid methyl ester 
• 308242-48-0 3-[2-benzylamino-7-chloro-5-(2-fluoro-phenyl)-3H-benzo[e][1,4]diazepin-3-yl]-propionic acid methyl ester 
• 308242-45-7 Methyl 3-[(3S)-7-chloro-5-(2-fluorophenyl)-2-(methylamino)-3H-1,4-benzodiazepin-3-yl]propanoate 
• 308242-53-7 3-[7-chloro-5-(2-fluoro-phenyl)-2-(2-hydroxy-ethylamino)-3H-benzo[e][1,4]diazepin-3-yl]-propionic acid methyl ester 
• 308242-47-9 3-[7-chloro-2-ethylamino-5-(2-fluoro-phenyl)-3H-benzo[e][1,4]diazepin-3-yl]-propionic acid methyl ester 

Relevant academic research and scientific papers

Novel benzodiazepine compound as well as preparation method and application thereof

The invention discloses a novel benzodiazepine compound as well as a preparation method and application thereof and belongs to the field of medicinal chemistry; the short-acting benzodiazepine derivative disclosed by the invention has the characteristics

SHORT-ACTING BENZODIAZEPINES

It has now been found that compounds of the present invention as described in Benzodiazepine derivatives of Formula (I) containing a carboxylic ester moiety and thereby capable of being inactivated by nonspecific tissue esterases in an organ-independent elimination mechanism and thereby providing a more predictable and reproducible pharmacodynamic profile. The compounds of the present invention are suitable for therapeutic purposes, including sedative-hypnotic, anxiolytic, muscle relaxant and anticonvulsant purposes and are useful to be administered intravenously in the following clinical settings: preoperative sedation, anxiolysis, and amnestic use for perioperative events; conscious sedation during short diagnostic, operative or endoscopic procedures; as a component for the induction and maintenance of general anesthesia, prior and/or concomitant to the administration of other anesthetic agents; ICU sedation.

Relating the structure, activity, and physical properties of ultrashort-acting benzodiazepine receptor agonists

The ultrashort-acting benzodiazepine (USA BZD) agonists reported previously have been structurally modified to improve aqueous solubility. Lactam-to-amidine modifications, replacement of the C5-haloaryl ring, and annulation of heterocycles are presented. These analogues retain BZD receptor potency and full agonism profiles.